LEO PHARMA A/S: Financial statements 2023
CVR: 56759514
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
LEO PHARMA A/S (CVR 56759514) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 11,392,000,000 and a net result of DKK -3,607,000,000 compared with EUR -4,110,000,000 the year before. That is an increase of 7.1% compared with the year before. The profit margin was -31.7%. Equity in the 2023 report amounted to DKK 4,525,000,000. The solvency ratio was 21.6%. The company had 4,490 employees in the financial year.
- Revenue
- DKK 11,392,000,000
- Gross Profit
- DKK 7,111,000,000
- Profit/Loss
- DKK -3,607,000,000
- Equity
- DKK 4,525,000,000
- Total Assets
- DKK 20,951,000,000
- Employees
- 4,490
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 11.4 mia. | 7.1 mia. | -3.6 mia. | 4.5 mia. | 4490 |
| 2022 | 10.6 mia. EUR | 6 mia. EUR | -4.1 mia. EUR | 1.9 mia. EUR | 5252 |
| 2021 | 10 mia. | 6 mia. | -4.9 mia. | 5.5 mia. | - |
| 2020 | 10.1 mia. | 6.8 mia. | -951 mio. | 6.9 mia. | - |
| 2019 | 10.8 mia. | 7.5 mia. | -1.3 mia. | 8.1 mia. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of September 20, 2023, is registered as an owner of LEO PHARMA A/S with an ownership share of 15%.
As of April 1, 2023, Sara Melissa Plov Hoff has joined the board of directors of LEO PHARMA A/S.
As of April 1, 2023, Thorsten Erik Ramsing has left the board of directors of LEO PHARMA A/S.
LEO PHARMA A/S has published its annual report for 2022. Revenue came to DKK 10,641,000,000, and the net result was DKK -4,110,000,000.
As of March 8, 2023, Jesper Mailind has joined the board of directors of LEO PHARMA A/S.
As of March 8, 2023, Paul Olivier Marie Navarre has joined the board of directors of LEO PHARMA A/S.
As of March 7, 2023, Jesper Mailind has left the board of directors of LEO PHARMA A/S.
As of March 7, 2023, Paul Olivier Marie Navarre has left the board of directors of LEO PHARMA A/S.
About LEO PHARMA A/S
LEO PHARMA A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 1962. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB. The management consists of Christophe Dominique Luc Charles Bourdon and Philip Harald Eickhoff. The board consists of Jesper Brandgaard (chair), Paul Olivier Marie Navarre, Peter Helt Jacobsen Haahr and Aino Anna Liisa Hurme. The company is owned by LEO Holding A/S and Cidron Savanna 4 SARL. The company has 1,047 employees (2026). In 2025, the company reported revenue of DKK 13,499,000,000 and a net result of DKK 2,489,000,000 compared with DKK -1,776,000,000 the year before. Equity in the 2025 report amounted to DKK 5,262,000,000.